Therefore, positive MUC1 or MUC2 in the preoperative cell block examination would be significant

because each of them is a predictor of malignant potential; thus, even if cell block H&E cytology findings were negative, the result of MUC would allow a rational decision on the management of IPMN patients. Karasaki et al22 also reported that classification based solely on mucin phenotype may offer important additional information on conventional image-based macroscopic this website types and morphological classification such as the presence of mural nodules, even if histological information regarding structural atypia is not obtained. There have been various attempts to distinguish benign

IPMNs from malignant ones using pancreatic juice. Molecular markers such as the K-ras gene mutation,24 p53 protein,25 telomerase activity,26 cyclooxygenase 2 expression,27 mesothelin mRNA,28 and aberrant methylation of tumor-related genes29 have been proposed as attractive diagnostic means; however, these have not been confirmed to be entirely specific. Histopathological analysis of EUS-guided FNA is another option for the diagnosis of IPMN malignancy. However, the sensitivity is reported to be as low as 44%30 because the histological grade of an IPMN varies throughout the ducts. Pelaez-Luna et al19 also showed in 28 patients with branch-duct type IPMNs that the specificity of EUS-guided FNA cytology was actually 100%, although its sensitivity was only 66%. In conclusion, pancreatic duct lavage cytology with Anticancer Compound Library chemical structure the cell block method may be useful not only for differentiating between benign and malignant branch-duct type IPMNs, but also for identifying its mucin type; thus, this could be an important diagnostic tool for deciding whether surgical intervention is indicated. Further studies in a larger series of patients are required to confirm the reliability of this diagnostic procedure. “
“Like Edoxaban autoimmune pancreatitis, there was a time when intraductal

papillary mucinous neoplasm (IPMN) was considered a “Japanese disease”; little of it was seen in the West. But ever since 4 cases were described by Ohashi et al1 in 1982, reports of this odd pancreatic tumor have increased worldwide.2 In the early days of ERCP, a diffusely dilated main pancreatic duct (PD) was assumed to be the result of obstruction at the level of the ampulla, and a dilated side branch was usually ignored or dismissed as a manifestation of chronic pancreatitis. We know better now: IPMNs are tumors of the pancreas arising from the ductal epithelium that range from benign to malignant, with a spectrum of dysplasia along the way. IPMNs are broadly divided into main duct and branch duct varieties, with infrequent mixed types that combine features of both.